ReviewFrontiers in neurology2025
Potential mechanisms and clinical applications of static magnetic field therapy in glioma.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glioblastoma Multiforme: Current Developments in Molecular Pathways, Magnetic Field-Based Interventions, and Personalized Therapy.Journal of clinical practice and research · 2026Review
- The Heart's Electromagnetic Field in Emotions, Empathy and Human Connection: Biosensor-Derived Insights into Heart-Brain Axis Mechanisms and a Basis for Novel BioMagnetoTherapies.Sensors (Basel, Switzerland) · 2026Review
- Mechanical Microenvironment-Dependent Tumor Growth Intervention: Recent Advances and Translational Outlook.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Static magnetic field (SMF) therapy, a non-ionizing and non-invasive treatment modality, has garnered increasing attention in glioma research. Gliomas, particularly glioblastoma (GBM), represent one of the most aggressive malignancies of the central nervous system, with limited therapeutic options and significant treatment-related toxicity. Emerging evidence suggests that SMF therapy exerts antitumor effects by inducing apoptosis, inhibiting cell proliferation, and modulating the tumor microenvironment, while minimizing damage to surrounding healthy tissues. Despite promising preclinical findings, research on SMF therapy remains in its early stages, and its precise mechanisms, clinical efficacy, and safety require further elucidation. This review summarizes current advancements in SMF therapy for gliomas, explores its potential as a standalone or adjunctive treatment, and discusses future research directions to optimize its therapeutic application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.